Ahmet KORKMAZ, Funda ÖZTUNA, Tevfik ÖZLÜ, Yılmaz BÜLBÜL, Savaş ÖZSU

Heparine bağlı trombositopeninin tedavisinde fondaparinuks: Bir olgu sunumu

Heparine bağlı trombositopeni heparin tedavisinin nadir, ancak ciddi bir komplikasyonudur ve trombotik komplikasyonlar nedeniyle yüksek morbidite ve mortaliteye sahiptir. Heparine bağlı trombositopeni heparin kullanımını takiben genellikle 5-14. günlerde gelişir. Heparine bağlı trombositopeni geliştiğinde heparin tedavisi kesilmeli ve direkt trombin inhibitörleri başlanmalıdır. Heparine bağlı trombositopeni standart heparin kullanımında düşük molekül ağırlıklı heparine göre daha sık gözlenmektedir. Bu yazıda düşük molekül ağırlıklı heparin profilaksisi sonrası, heparine bağlı trombositopeni gelişen bir olgu güncel literatür eşliğinde sunulmuştur.

Fondaparinux treatment in heparin induced thrombocytopenia: a case report

Heparin induced thrombocytopenia is a serious complication of heparin therapy that has a high levels of morbidity and mortality due to thrombotic complications. Heparin induced thrombocytopenia usually develops between days 5 and 14 (inclusive) following initiation of heparin. When heparin induced thrombocytopenia is suspected, heparin should be discontinued and treatment with a direct thrombin inhibitor should be initiated. Heparin induced thrombocytopenia occurs more frequently with unfractionated heparin than with low molecular weight heparin. In this manuscript, we presented a case diagnosis with heparin induced thrombocytopenia who was given low molecular weight heparin for prophylaxis. We tried to make an overview of new treatment choices along with current literature.

PDF

___

1. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood 2008; 112: 2606-15.
2. Kelton JG. Heparin-induced thrombocytopenia: an overview. Blood Rev 2002; 16: 77-80.
3. Baglin TP. Heparin-induced thrombocytopenia/thrombosis syndrome (HIT): diagnosis and treatment. Platelets 1997; 8: 72-82.
4. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 2007; 131: 1644-9.
5. Levine RL, McCallum D, Hursting MJ. How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia? Chest 2006; 130: 631-2.
6. Warkentin TE, Grienacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 2004; 126: 311-37.
7. Franchini M. Heparin-induced thrombocytopenia: an update. Thrombosis Journal 2005; 3: 14.
8. Warkentin TE, Greinacher A, Koster A, Lincoff MA. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008; 133: 340-80.
9. Demir M, Duran E, Yigitbasi O, Vural O, Kurum T, Yuksel M, et al. Incidence of antiheparin-platelet factor 4 antibodies and heparin- induced thrombocytopenia in Turkish patients undergoing cardiac surgery. Clin Appl Thromb Hemost 2007; 13: 279-84.
10. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006; 108: 2937- 41. Epub 2006 Jul 20.
11. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
12. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparininduced thrombocytopenia. Am J Med 1999; 106: 629-35.
13. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-7.
14. Akagün T, Sönmez M, Yılmaz M ve ark. Heparinin indüklediği trombositopenide fondaparinux tedavisi: Olgu sunumu. International Journal of Hematology and Oncology 2006; 16: 141-4.
15. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92: 494-7.
16. Sünmez S, Okumuş G, Kiyan E, Ece T, Arseven O. A case of heparin induced thrombocytopenia treated with lepirudin infusion: case report. Tuberk Toraks 2006; 54: 185-8.
17. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced trombocytopenia. Arch Intern Med 2004; 164: 361-9.
18. Warketin TE, Kelton JG. Heparin-induced thrombocytopenia. Ann Rev Med 1989; 40: 31-44.
19. Srinivasan AF, Rice L, Bartholomew JR, Rangaswamy C, La Perna L, Thompson JE, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004; 164: 66-70.
20. Bauer KA. New anticoagulants. Curr Opin Hematol 2008; 15: 509-15.
21. http://www.fda.gov/medwatch/SAFETY/2005/MAY_ PI/Arixtra_PI.pdf
22. Hassell K. Heparin-induced thrombocytopenia: Diagnosis and management. Thromb Res 2008; 123: 16-21.
23. Chong BH. Heparin-induced thrombocytopenia. Thromb Haemost 2003; 1: 1471-8.
24. Rubin N. Treatment of heparin-induced thrombocytopenia with thrombosis (HIT) in pregnancy with fondaparinux. Blood 2003; 102: 4190.
25. Warkentin T, Maurer B, Aster R. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-5.
26. Rota E, Bazzan M, Fantino G. Fondaparinux related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced thrombocytopenia (HIT). Thromb Haemost 2008; 99: 779-81.
27. Turpie AG. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Expert Opinion on Drug Safety 2005; 4: 707-21.
28. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001; 85: 950-7.
29. Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Sem Hematol 1998; 35: 26-34.
30. Lubenow N, Eichler P, Lietz T, Greinacher A; Hit Investigators Group. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005; 3: 2428-36.
31. Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, et al; GEHT-HIT Study Group. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 2006; 108: 1492-6. Epub 2006 May 11.
32. Lepirudin Intravenous. Monograph-Lepirudin. Medscape. com
33. Warkentin TE, Kelton JG. Temporal aspects of heparin induced thrombocytopenia. N Engl J Med 2001; 344: 1286-92.
34. Bradner J, Hallisey RK, Duter DJ. Fondaparinux in the treatment of heparin-induced thrombocytopenia. Blood 2004; 104: 1775.
35. Kuo KH, Kovacs MJ. Fondaparinux: A potential new therapy for HIT. Hematology 2005; 10: 271-5.